Tablet formulation for sustained drug-release

Details Tablet formulation for sustained drug-release Tablet formulation for sustained drug-release

A - Human Necessities

61

K

A61K 9/26 (2006.01) A61K 47/36 (2006.01)

Patent

CA 2591806

Disclosed is a pharmaceutical sustained release tablet for oral administration of a drug which is made of a compressed blend of at least three dry powders including a powder of a drug, a powder of a sustained release matrix for the drug, and a powder of at least one electrolyte. The sustained release matrix consisting of an un-cross-linked high amylose starch wherein the high amylose is substituted by at least one organic substituent comprising at least one carboxyl group. This organic substituent is preferably a carboxyalkyl having 2 to 4 carbon atoms, its salt or mixture thereof. This tablet has the advantage of having an improved integrity.

L'invention concerne un comprimé pharmaceutique à libération prolongée destiné à l'administration par voie orale d'un médicament renfermant un mélange comprimé d'au moins trois poudres sèches, soit une poudre d'un médicament, une poudre d'une matrice à libération prolongée pour le médicament et une poudre d'au moins un électrolyte. La matrice à libération prolongée est constituée d'un amidon non réticulé à forte teneur en amylose, l'amylose étant substituée par au moins un substituant organique comprenant au moins un groupe carboxyle. Ce substituant organique est de préférence un carboxyalkyle comprenant entre 2 et 4 atomes de carbone, son sel ou un mélange correspondant. Ledit comprimé présente l'avantage de posséder une intégrité améliorée.

Affiliated with

Also associated with

Rating

Tablet formulation for sustained drug-release does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tablet formulation for sustained drug-release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tablet formulation for sustained drug-release will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1389620